Acquisition by Hawley Roger of 307714 shares of Dare Bioscience subject to Rule 16b-3
| DARE Stock | USD 2.40 0.01 0.42% |
About 55% of Dare Bioscience's investor base is interested to short. The analysis of overall sentiment of trading Dare Bioscience stock suggests that many investors are impartial at this time. The current market sentiment, together with Dare Bioscience's historical and current headlines, can help investors time the market. In addition, many technical investors use Dare Bioscience stock news signals to limit their universe of possible portfolio assets.
Filed transaction by Dare Bioscience Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Dare Bioscience Fundamental Analysis
We analyze Dare Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dare Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dare Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Dare Bioscience is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Dare Bioscience Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dare Bioscience stock to make a market-neutral strategy. Peer analysis of Dare Bioscience could also be used in its relative valuation, which is a method of valuing Dare Bioscience by comparing valuation metrics with similar companies.
Peers
Dare Bioscience Related Equities
| CRVO | CervoMed | 7.72 | ||||
| NDRA | ENDRA Life | 5.37 | ||||
| QTTB | Q32 Bio | 2.59 | ||||
| CNTB | Connect Biopharma | 2.00 | ||||
| ACHV | Achieve Life | 1.55 | ||||
| VTVT | VTv Therapeutics | 1.04 | ||||
| XBIO | Xenetic Biosciences | 0.62 | ||||
| COCP | Cocrystal Pharma | 14.95 |
Complementary Tools for Dare Stock analysis
When running Dare Bioscience's price analysis, check to measure Dare Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dare Bioscience is operating at the current time. Most of Dare Bioscience's value examination focuses on studying past and present price action to predict the probability of Dare Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dare Bioscience's price. Additionally, you may evaluate how the addition of Dare Bioscience to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |